Is alteplase a biologic drug?

Is alteplase considered a biologic drug?

Alteplase is considered a biologic medicine because it is produced using biological manufacturing processes and it acts as a protein-based therapeutic (a recombinant tissue plasminogen activator, tPA). That protein/biologic character is why it is commonly grouped with other biologics in clinical and regulatory discussions.

Does alteplase get classified like a biosimilar?

Yes. Because alteplase is a protein drug, products that are intended to be highly similar (or biosimilar-type) are discussed in the same overall “biosimilar/biologic” framework as other protein biologics, rather than like small-molecule generics.

What’s the practical difference vs “small-molecule” drugs?

Unlike small-molecule drugs (typically chemically synthesized), alteplase is a protein biologic. That difference matters for how manufacturing changes can affect structure/function and why biologics are not always interchangeable with small-molecule generics.

Sources

I can add specific citations to regulatory or authoritative classification pages, but I need the country/regulator context (for example, FDA/EMA/UK MHRA) and whether you mean “biologic” under US labeling rules or “biologic” in a broader general sense.